Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 7/20 | 0.50 |
| ▸ | RAB9A | P51151 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | TOP2A | P11388 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4469414 | 1.00 | LMNA (0.67) | LMNANPC1RAB9AMAPTL3MBTL1 | |
| SCHEMBL7595958 | 0.79 | TOP2A (0.66) | LMNANPC1RAB9AMAPTL3MBTL1 | |
| SCHEMBL23550666 | 0.79 | LMNA (0.55) | LMNANPC1RAB9AMAPTL3MBTL1 | |
| SCHEMBL2931559 | 0.79 | LMNA (0.54) | LMNANPC1RAB9AL3MBTL1CDK5 | |
| SCHEMBL22872697 | 0.79 | LMNA (0.54) | LMNANPC1RAB9AL3MBTL1CDK5 | |
| SCHEMBL10157708 | 0.79 | LMNA (0.54) | LMNANPC1RAB9AL3MBTL1CDK5 | |
| SCHEMBL18653617 | 0.78 | NPC1 (0.54) | LMNANPC1RAB9AL3MBTL1CDK5 | |
| SCHEMBL640709 | 0.76 | KDM4E (0.59) | LMNANPC1RAB9AL3MBTL1CDK5 | |
| SCHEMBL1428592 | 0.76 | KDM4E (0.54) | LMNANPC1RAB9AL3MBTL1TDP1 | |
| SCHEMBL834329 | 0.76 | KDM4E (0.54) | LMNANPC1RAB9AL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691992-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210253605-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | ANACOR PHARMACEUTICALS INC (US) | 2021-08-19 | — | — | US | disclosed |
| US-10961261-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| EP-3609504-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | Anacor Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018160845-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
| US-8268835-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-7622605-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090281122-A1 | Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase, and Compositions and Treatments Using the Same | PFIZER INC | 2009-11-12 | — | — | US | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-7151105-B2 | Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281122-A1 | Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase, and Compositions and Treatments Using the Same | RNASE1, GTF3C4, POLRMT | LMNA 2519/4885NPC1 219/4885RAB9A 3785/4885 |
| US-11691992-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | LMNA 2380/4885NPC1 818/4885RAB9A 2351/4885 |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, GTF3C4, POLRMT | LMNA 2519/4885NPC1 219/4885RAB9A 3785/4885 |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, GTF3C4, POLRMT | LMNA 2519/4885NPC1 219/4885RAB9A 3785/4885 |
| US-20210253605-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | OXA1L, AOX1, EPX | LMNA 3262/4885NPC1 645/4885RAB9A 1725/4885 |
| US-10961261-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | LMNA 2380/4885NPC1 818/4885RAB9A 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.